{"ticker": {"uuid": "d3611432-dbba-40bf-bbc5-6c1a83eaf590", "symbol": "VLA", "name": "Valneva SE", "exchange": "VIE", "country": "AT", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "IXIARO from Valneva SE - travel vaccine with a clear safety profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPWGpER0tiOUJHMzlMbVpfcWdBeEhDTjNQdEN5VWZzSDB2MFZRRWNoV3d1eUx3dDF1Q3dmRWw1LWRjR1ctdWhya0hrcFNXX19scVdCQi1JZmE5RzBLZWVyUnM0X3RSeG1GRV9PZl82cDRxLWMwNGpQTUM5Z3BMWTJuZ3JMOE5TMm9VcjVHS0FDbDF2SjdBc1NsQ2lWY3JXclEyd3k4QTBVRDZkallJRDZXOHlqRXRNQ0NXa1JSQ2dtdDVFUQ?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-06-27T15:26:11+00:00", "published_display": "27 Jun 2026 15:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "\u20ac5.28: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE Stock 12\u2011Month Price Target Cut to $12.98, Implies 116% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQYU9TWGRrdmlJTExHMV8xRnlRRVhQNWxSZ0hId0F2cHRmSlpaOGJ6bmJ6UDdJdFJnWFhxZ3pTdGJseE9hVUw3OHMzTGQ5UlNLUHpUQThEUDByMWJJQjFidjhBVWVzZXFJUEM2UWVtaUtEeG04bVc4bmZVMXdwa0E4UTB4R0VRVDN0cUdaY2c4TTlrWmYyRkJhSHZLSEhaUEFLelMxWkZlTmpJejVWYzBPcWx5ZVU4RUcyRE0xQTljYUpKMEw5d3J0LW1Qdk4?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPMVhJNWNQbi1WbjNnZVR3UVBrdTY0eVdTQ2tZWmJ1YlRWM2doWjAxb0owX3JTUFA3TFE3T05VU3Y5R2VOX1BVWVZfVjV6S0JsTHlHVlhQR1VaQkN4d0h3N0JmTnJfSWllWGRNek5NMGQyNFBKcldyTV9HYTJSMzEzWkxKNndMU1BFclZFbnd2dkZEaUZFaUk0aE5GWUJCNlFVSTNzSFk2QVZTWDRnUXp3dlZWOGVoenFaa1ByZUVUZDBKUENHX2xOWVo1NVdISDQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva in the green despite guidance cut and restructuring", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxObHhra19UT25BaE5BQ3JZdGoxd1NLWHpNQzFCMGFCNU1sWE9Uc2hwYWpEeU1jMW81aGstQ2l3ckkybTIyV3FCRkhSVFdlYUg3bGE2aC1neV9LUVFHczJZazZnWEVqazdReUZVclJzMlplSlVjOUpmTGIxY0VvVWJIZ3g3TlltckNYbXI1bVdETnFZeTlMaUNpZG1NbXlmdzNPZEZiR3E0cUJPazNRQzNyRmJB?oc=5", "source_name": "marketscreener.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQaGF2V1dxWjJZM0ZEV3A0bEFmd080ZEZzSm1IYWZPa3JueG5PNXQxYkZaQjFBSElURHUyQ21iOWJ5WFZ3S1BEUTRSeERCdXUzeFYwOFU2TUNmbGgwQVNtcEYyaXE2S3pKMWw0RFJjSDNnbGNwaFlZdi1pLUZHRndsbkVUZmVoN0pkallYWG9pazFrMXdfQ0FtOFZzZUV5ekhIejZMMjhndnQ3M3R6NGhnTVpkcVh0Q3MzZGJZMkdWRGtFY2tFZHhWMEV3bGwxODN2TW1zdm5wdw?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva Stock Forecast 2026\u20132030 | Future Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOUzZnYncxUkx1bDZjMnVTWktyRkF5TU1HT1hDbjZpOUlvdHJaUFJtaU1xNmNCOFkzbkJWTUNvNFAwUDltcXYydXdPM3U5UkwyOXZUeHB5Z096SFF1T2cwcUlhajNQNjZybDBSLXZMM0FEYm9nbDlLZlNJZ2YwOHlhQQ?oc=5", "source_name": "Capital.com", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva withdraws application for standard US approval of its chikungunya shot", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOQ3FRY25VZjZlRTZiSGNrV25hU2QyNWpUN3JvNy1zWGNNSEtKM0ZuUG1TMlY0ZTBqN2RQZjU0ZUpWZTdob1Z3UUZTalB6RzVORkpVQkdBWVRvU0VmZE9KYlpZU3FEaGE2bFROS3J3UHV3NmJfdTVyQ3ZBYzVWa2x2ckFXQnVqVm1raFl3MDFLY0RlX3VodW5kOGpXdkZTbkl3RUpZbmFKUGpiYzBKMjJoV3pDRnNEblpqQl9INDBPMnFCeVBFWTEzb1NCbmJwX1FJQno1Yk5fekxIaFk?oc=5", "source_name": "Reuters", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva: the return of biotech euphoria?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNS0NCNG9HYUtHWnBLNmxDMm1qRkppYmNHVm1oQTd5QW9QTGVnWEN5TmhMbXY1Q3I5WVlmZWhXZ2h1bk5xd3A3Z1hyU3dJd0NSTmFaaEhGUnFNUEJQT2ZHWkpzYUdfTXZsS0JGTy01SUxCTG9faV9fRWhma1pGQUQtWU1oc21BVS1nVW5NRTQzczI1SlNzNlE?oc=5", "source_name": "marketscreener.com", "published_at": "2025-08-13T07:00:00+00:00", "published_display": "13 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "IXIARO from Valneva SE - travel vaccine with a clear safety profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPWGpER0tiOUJHMzlMbVpfcWdBeEhDTjNQdEN5VWZzSDB2MFZRRWNoV3d1eUx3dDF1Q3dmRWw1LWRjR1ctdWhya0hrcFNXX19scVdCQi1JZmE5RzBLZWVyUnM0X3RSeG1GRV9PZl82cDRxLWMwNGpQTUM5Z3BMWTJuZ3JMOE5TMm9VcjVHS0FDbDF2SjdBc1NsQ2lWY3JXclEyd3k4QTBVRDZkallJRDZXOHlqRXRNQ0NXa1JSQ2dtdDVFUQ?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-06-27T15:26:11+00:00", "published_display": "27 Jun 2026 15:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "\u20ac5.28: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPb1EzVWl5MzZfYnFJSGFPR2FZb1VuamRUaVdTa0xXMW9KOGlSZXVZTE1fOHhjVGFUMHZyZUllSVIwZ3dmQ0FoNjBDakYzcmVtc0cxbW8tc3FFODhUeFBRWUJqYVQzQ1JjSU5WYy10UTRpRmo2UFZua1VqcGpDSUozSk5SbVlDSTNEVWk1bkhIR3RQamJfU2ZrQTZXZm51VUJmV3hRekpWWkhQejlaQklPTjFFd3RlZjdHY1BFYTNnRnhPb044czNJb252R1BQRExGRlZzSjMtWlpUYzlT0gHiAUFVX3lxTE1kVVFiR21fV2dwTjl2SXZrVkQ2RzI0dnRLOVRnTEg1b0FrdEgyUHA0UWRiaGowY1RzVEJBZWNoZGhjRjdsaFYtV29xd2Qxdk90WDRWSHNwZ0daRnRLWDZ0c0xmV2d3MGdzVWZCOVh2LURBanlHRkxiZUhpTGxwRjVZblJjT21lalZJY3d4TWtTT2RNVHVBTHR2MXNwRWlTUVp0aV9YVFlGS29IcTV4YmRTdW5neTk2Y29fTC1CWmk0SFNpV29PdE1TUGRHVDE0SzZ5dnlaREJzOUJ4YjdnazZJQmc?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE Stock 12\u2011Month Price Target Cut to $12.98, Implies 116% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQYU9TWGRrdmlJTExHMV8xRnlRRVhQNWxSZ0hId0F2cHRmSlpaOGJ6bmJ6UDdJdFJnWFhxZ3pTdGJseE9hVUw3OHMzTGQ5UlNLUHpUQThEUDByMWJJQjFidjhBVWVzZXFJUEM2UWVtaUtEeG04bVc4bmZVMXdwa0E4UTB4R0VRVDN0cUdaY2c4TTlrWmYyRkJhSHZLSEhaUEFLelMxWkZlTmpJejVWYzBPcWx5ZVU4RUcyRE0xQTljYUpKMEw5d3J0LW1Qdk4?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPMVhJNWNQbi1WbjNnZVR3UVBrdTY0eVdTQ2tZWmJ1YlRWM2doWjAxb0owX3JTUFA3TFE3T05VU3Y5R2VOX1BVWVZfVjV6S0JsTHlHVlhQR1VaQkN4d0h3N0JmTnJfSWllWGRNek5NMGQyNFBKcldyTV9HYTJSMzEzWkxKNndMU1BFclZFbnd2dkZEaUZFaUk0aE5GWUJCNlFVSTNzSFk2QVZTWDRnUXp3dlZWOGVoenFaa1ByZUVUZDBKUENHX2xOWVo1NVdISDQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva in the green despite guidance cut and restructuring", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxObHhra19UT25BaE5BQ3JZdGoxd1NLWHpNQzFCMGFCNU1sWE9Uc2hwYWpEeU1jMW81aGstQ2l3ckkybTIyV3FCRkhSVFdlYUg3bGE2aC1neV9LUVFHczJZazZnWEVqazdReUZVclJzMlplSlVjOUpmTGIxY0VvVWJIZ3g3TlltckNYbXI1bVdETnFZeTlMaUNpZG1NbXlmdzNPZEZiR3E0cUJPazNRQzNyRmJB?oc=5", "source_name": "marketscreener.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQaGF2V1dxWjJZM0ZEV3A0bEFmd080ZEZzSm1IYWZPa3JueG5PNXQxYkZaQjFBSElURHUyQ21iOWJ5WFZ3S1BEUTRSeERCdXUzeFYwOFU2TUNmbGgwQVNtcEYyaXE2S3pKMWw0RFJjSDNnbGNwaFlZdi1pLUZHRndsbkVUZmVoN0pkallYWG9pazFrMXdfQ0FtOFZzZUV5ekhIejZMMjhndnQ3M3R6NGhnTVpkcVh0Q3MzZGJZMkdWRGtFY2tFZHhWMEV3bGwxODN2TW1zdm5wdw?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva Stock Forecast 2026\u20132030 | Future Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOUzZnYncxUkx1bDZjMnVTWktyRkF5TU1HT1hDbjZpOUlvdHJaUFJtaU1xNmNCOFkzbkJWTUNvNFAwUDltcXYydXdPM3U5UkwyOXZUeHB5Z096SFF1T2cwcUlhajNQNjZybDBSLXZMM0FEYm9nbDlLZlNJZ2YwOHlhQQ?oc=5", "source_name": "Capital.com", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva withdraws application for standard US approval of its chikungunya shot", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOQ3FRY25VZjZlRTZiSGNrV25hU2QyNWpUN3JvNy1zWGNNSEtKM0ZuUG1TMlY0ZTBqN2RQZjU0ZUpWZTdob1Z3UUZTalB6RzVORkpVQkdBWVRvU0VmZE9KYlpZU3FEaGE2bFROS3J3UHV3NmJfdTVyQ3ZBYzVWa2x2ckFXQnVqVm1raFl3MDFLY0RlX3VodW5kOGpXdkZTbkl3RUpZbmFKUGpiYzBKMjJoV3pDRnNEblpqQl9INDBPMnFCeVBFWTEzb1NCbmJwX1FJQno1Yk5fekxIaFk?oc=5", "source_name": "Reuters", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva: the return of biotech euphoria?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNS0NCNG9HYUtHWnBLNmxDMm1qRkppYmNHVm1oQTd5QW9QTGVnWEN5TmhMbXY1Q3I5WVlmZWhXZ2h1bk5xd3A3Z1hyU3dJd0NSTmFaaEhGUnFNUEJQT2ZHWkpzYUdfTXZsS0JGTy01SUxCTG9faV9fRWhma1pGQUQtWU1oc21BVS1nVW5NRTQzczI1SlNzNlE?oc=5", "source_name": "marketscreener.com", "published_at": "2025-08-13T07:00:00+00:00", "published_display": "13 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 75, "total_relevant": 9, "sentiment_summary": {"positive": 0, "negative": 3, "neutral": 6, "score": 45, "total": 9, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 68, "events": [{"event": "general", "label": "Market update", "weight": 1.65, "count": 3}, {"event": "earnings", "label": "Earnings", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.9, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 2.2, "latest_week": "2026-07-10", "one_week_move": -6.6, "four_week_move": -3.9, "twelve_week_move": -12.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.466796, "market_dynamics_buy_signal": false, "relative_strength": -50.784345, "fair_value_gap": -39.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.1915, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.6% over one week, -3.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "marketscreener.com", "count": 2}, {"label": "ad-hoc-news.de", "count": 1}, {"label": "simplywall.st", "count": 1}, {"label": "TradingView", "count": 1}, {"label": "Investing.com", "count": 1}, {"label": "PR Newswire", "count": 1}, {"label": "Capital.com", "count": 1}, {"label": "Reuters", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 9}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}, {"label": "Earnings", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "45/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "68/100 classification confidence."}, {"label": "Company focus", "value": "9", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.6% over one week, -3.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "IXIARO from Valneva SE - travel vaccine with a clear safety profile"}], "updated_at": "2026-07-18T01:55:49.757940+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}